Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer
Study Details
Study Description
Brief Summary
This phase II trial studies the effect of adaptive radiation planning in reducing side effects associated with radiation treatment and immunotherapy in patients with stage II-IV non-small cell lung cancer. Prior to radiation, patients undergo simulation, where they are positioned on the treatment table in a manner that can be reproduced each time they receive treatment in order to reach the tumor exactly at the same spot each time. However, a patient's tumor may shrink as they receive radiation, exposing healthy tissue to radiation as well. Adaptive radiation planning involves re-designing a treatment plan at set intervals. The purpose of this study is to see whether establishing set time points through adaptive radiation planning, regardless of whether the doctor notices a significant decrease in tumor size, will reduce some of the side effects associated with radiation treatment and immunotherapy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
N/A |
Detailed Description
PRIMARY OBJECTIVE:
- To evaluate whether implementing set intervals for radiation replanning reduces cardiopulmonary toxicity and preserves healthy lung and heart tissue, with the intention of establishing a new standard treatment modality.
OUTLINE:
Patients undergo computed tomography (CT) stimulation with or without intravenous (IV) contrast over 1.5 hours on days -15 to -1, then undergo standard of care (SOC) chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29.
After completion of study, patients are followed up at 3-12 weeks, and then every 6 months for approximately 2 years.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Supportive care (CT simulation, contrast agent) Patients undergo CT stimulation with or without IV contrast over 1.5 hours on days -15 to -1, then undergo SOC chemoradiation on days 1-40. Patients also undergo additional CT scan simulations without IV contrast over 20 minutes each on days 15 and 29. |
Procedure: Computed Tomography
Undergo CT simulation
Other Names:
Other: Contrast Agent
Given IV
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Determine if adaptive radiation therapy reduces radiation induced pneumonitis rates [At 6 months post chemoradiation]
Will be analyzed using a one-sided z-test to determine if reduction in radiation doses to organs at risk compared will result in a lower rate of pneumonitis compared to historical controls.
Secondary Outcome Measures
- Determine if adaptive radiation therapy reduces radiation doses to heart and lung [Baseline up to day 29 of treatment]
Will be compared to computed tomography simulation without adaptation of lung tumor volumes. The dosimetric parameters collected over the treatment period will be analyzed using linear mixed models with appropriate intra-correlation structures.
- Dosimetric changes in lung, heart, and esophageal dosimetry parameters in patients treated with adaptive radiation planning [Baseline up to day 29 of treatment]
Will be compared to computed tomography simulation without adaptation of tumor volumes. The dosimetric parameters collected over the treatment period will be analyzed using linear mixed models with appropriate intra-correlation structures.
- Change in toxicities, including cardiac and esophageal toxicities [Baseline up to 25 months after chemoradiation]
Will be compared to historical controls who have not undergo adaptive re-planning at specified time points using Common Terminology Criteria for Adverse Events version 5.0.
- Toxicity correlation to disease-free survival (DFS)/progression-free survival (PFS)/overall survival (OS) [Up to 25 months after chemoradiation]
Will determine if toxicity correlates to DFS/PFS/OS using historical controls for comparison, estimated via Kaplan-Meier product limit and compared among different toxicity levels using a log-rank test.
- Tumor volume reduction [Up to 25 months after chemoradiation]
Will determine if tumor volume reduction correlates to immunotherapy response.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information
-
Histologically or cytological evidence of locally advanced, biopsy-proven, stage II (inoperable), III-or oligometastatic stage IV NSCLC planned to be treated with chemoradiation with concurrent or adjuvant immunotherapy
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Adequate organ and marrow laboratory values for radiation therapy deemed by appropriate the investigator obtained within 14 days prior to registration for protocol therapy
-
Women of childbearing potential (WOCBP) must obtain a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) at day -30 to day 0
-
Women of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of contraception during the time of the study period
-
Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year
Exclusion Criteria:
-
History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the site investigator
-
Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial
-
Active central nervous system (CNS) metastases (if symptomatic or without prior brain imaging, subjects must undergo a head computed tomography [CT] scan or brain magnetic resonance imaging [MRI] within 28 days prior to registration for protocol therapy to exclude brain metastases)
-
Treatment with any investigational agent within 28 days prior to registration for protocol therapy
-
Prior chemotherapy, adjuvant therapy, or radiotherapy for lung cancer other than standard concurrent chemoradiation or up to 2 cycles of consolidation therapy
-
Active second cancers
-
History of psychiatric illness or social situations that would limit compliance with study requirements
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | United States | 08903 |
Sponsors and Collaborators
- Rutgers, The State University of New Jersey
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Salma K Jabbour, Rutgers Cancer Institute of New Jersey
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Pro2020002153
- NCI-2020-08292
- Pro2020002153
- 032009
- P30CA072720